Clinical Trial Update: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee [Phase 3]

View source ↗

Summary

Ongoing Phase 3 study evaluating Orforglipron (LY3502970) in adults with obesity or overweight and knee osteoarthritis; recruitment is currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Osteoarthritis

Drugs mentioned

• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Osteoarthritis | Phase 3 | Status: RECRUITING